The Filatov Institute of Eye Diseases and Tissue Therapy
11
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration
Role: lead
Intraocular Gas Tamponade for Treatment of Large Idiopathic Macular Holes
Role: lead
Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening
Role: lead
ARTIFICIAL INTELLIGENCE FOR MASS SCREENING OF THE DIABETIC RETINOPATHY IN THE CHERNIVTSI REGION (Pilot Study)
Role: lead
Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia
Role: lead
Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment
Role: lead
Brolucizumab for CNV Associated With Pathologic Myopia
Role: lead
Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis
Role: lead
Antiangiogenic Therapy of CNV Associated With Angioid Streaks
Role: lead
Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy
Role: collaborator
Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
Role: lead
All 11 trials loaded